It is that approved products give clinicians and patients a clearer framework for discussing risks, expected monitoring, prescription requirements, and affordability
Diabetes prescriptions may be more stable and predictable, while obesity-related prescriptions can involve more frequent dose adjustments, therapy initiation, and discontinuation
Promotion of service and medicinal products for weight loss by Menwell Ltd trading as Voy (December 2025)
Both prescription medications are classified as controlled substances, so they both are stringently monitored and come with the risk of abuse and physical or psychological dependence
Image Credit: ichefboy / Shutterstock
However, FAERS has well-known limitations: Reports are spontaneous and incomplete Reporting stimulated by media attention and warnings No denominator (unknown number of exposed users) Thyroid cancer not subtype-adjudicated Confirmation bias (clinicians primed to connect drug and outcome) FAERS can answer: "Is this being reported more?" It cannot answer: "Does this drug cause thyroid cancer?" Appropriate Use of FAERS: FAERS findings are hypothesis-generating signals requiring controlled observational worknot evidence of causality